Mark Gurley, MD
Otolaryngology · Knoxville, TNNPI 1285751818
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,812 of the $8,052 with a category attached, or 72.2%. 30 manufacturers reported payments, led by Intersect ENT, Inc. at 38.7% of the total. Reporting peaked in 2019 at $3,561 and has fallen 69.4% since, to $1,088 in 2025. Among otolaryngology clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 187 payments — averaging $43.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intersect ENT, Inc.$3K
- Stryker$1K
- Sanofi$757
- Regeneron Healthcare Solutions, Inc.$614
- Acclarent, Inc$494
- GSK$419
- plus $1K from 24 others
What the payments were for
- Consulting fees$1001%
- Travel & lodging$2,00825%
- Food & beverage$5,81272%
- Education$1312%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intersect ENT, Inc. | 18 | $3,112 |
| Stryker | 21 | $1,220 |
| Sanofi | 32 | $757 |
| Regeneron Healthcare Solutions, Inc. | 27 | $614 |
| Acclarent, Inc | 15 | $494 |
| GSK | 22 | $419 |
| Integra Lifesciences Corporation | 6 | $273 |
| Aerin Medical Inc. | 2 | $158 |
| Optinose US, Inc. | 7 | $135 |
| Medtronic | 3 | $134 |
| Sanofi-aventis U.S. LLC | 2 | $112 |
| Merck | 6 | $110 |
| Novartis | 4 | $71 |
| Organogenesis Inc. | 2 | $44 |
| Inspire Medical Systems, Inc. | 2 | $38 |
| AstraZeneca | 2 | $38 |
| Davol Inc. | 1 | $37 |
| Acera Surgical, Inc. | 2 | $36 |
| Hikma Pharmaceuticals USA | 2 | $33 |
| Neurent Medical Limited | 1 | $29 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $25 |
| Baxter Healthcare | 1 | $25 |
| Alk-abello, Inc | 1 | $23 |
| Covidien LP | 1 | $21 |
| Phadia US Inc. | 1 | $20 |
| Greer Laboratories, Inc. | 1 | $20 |
| Cook Medical LLC | 1 | $16 |
| Xoran Technologies LLC | 1 | $14 |
| Ambu Inc. | 1 | $13 |
| Olympus America Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SINUVA$2,572
- PROPEL$478
- XPRESS ENT DILATION SYSTEM$312
- ENTELLUS - XPRESS ENT DILATION SYSTEM$285
- DUPIXENT$244
- Acclarent Aera$173
- Inspira Air$173
- RELIEVA SPINPLUS NAV$173
- TruDi Probe$173
- FIAGON NAVIGATION UNIT$159
- Vivaer RF Stylus$142
- OPERON$123
- 1688$123
- TruDi Nav Cable$116
How this compares
$8,052 in reported general payments places this provider in the 90th percentile of 191 otolaryngology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 34 | $129,843 |
| RyaltrisOlopatadine Hcl/Mometasone | 26 | $7,714 |
| Ipratropium Bromide | 204 | $7,649 |
| Fluocinolone Acetonide Oil | 94 | $5,225 |
| Fluticasone Propionate | 238 | $3,956 |
| Azelastine Hcl | 54 | $2,420 |
| Epinephrine | 16 | $2,343 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 15 | $1,886 |
| Olopatadine Hcl | 19 | $1,730 |
| Montelukast Sodium | 129 | $1,252 |
| Ofloxacin | 28 | $1,014 |
| Famotidine | 92 | $779 |
| Mupirocin | 72 | $758 |
| Doxycycline Hyclate | 40 | $668 |
| Cefdinir | 22 | $612 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USARyaltris, Epinephrine | $33 | $10,05742 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 191 otolaryngology providers in Tennessee.
Other otolaryngology in Knoxville
- Nicholas PanellaKnoxville$5K
- Jaron DenskyKnoxville$4K
- Samuel OverholtKnoxville$3K
- Rakesh ChandraNashville$381K
- David FortuneHermitage$298K
- Grady BryantHermitage$74K
- Marion GillespieMemphis$67K
- Clyde MathisonFarragut$66K
- Dean KlugGermantown$37K
- Michael TopfNashville$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.